Cardinal Health (CAH) shares declined 0.2% in pre-market trading at 08:48 EST on Wednesday. The company announced on Wednesday its $1.9 billion acquisition of medical technology firm Urogen Pharma Ltd. (URGN), causing shares to drop as much as 4.2% during intraday trading before closing down 2.7% at $102.45.
The all-cash transaction values URGN at $16 per share, representing a 14% premium over its Tuesday closing price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.